Venous Thromboembolism: A Review

Journal of Reproductive Medicine for the Obstetrician and Gynecologist

Volumn 48, Issue 11 SUPPL., 2003, Pages 911-920

  Thorneycroft, Ian H ^a   Goldzieher, Joseph W ^b  

^a Bay Area Physicians for Women   (United States)

^b NONE

Author keywords

Thromboembolism; Venous thromboembolism

Indexed keywords

ALTEPLASE; ANTITHROMBOCYTIC AGENT; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A INHIBITOR; BLOOD CLOTTING FACTOR 9A INHIBITOR; DALTEPARIN; ENOXAPARIN; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; HEPARINOID; HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT; RETEPLASE; STREPTOKINASE; THROMBIN INHIBITOR; TINZAPARIN; UNCLASSIFIED DRUG; UROKINASE; WARFARIN;

ANTICOAGULANT THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COMPRESSION THERAPY; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DEEP VEIN THROMBOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DOSE CALCULATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG SAFETY; EMBOLECTOMY; EPIDEMIOLOGICAL DATA; HUMAN; INCIDENCE; LEG COMPRESSION; LUNG EMBOLISM; META ANALYSIS; MOBILIZATION; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; SEX DIFFERENCE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

AGE FACTORS; AGING; ANTICOAGULANTS; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LIFE STYLE; MALE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PULMONARY EMBOLISM; RISK FACTORS; SMOKING; THROMBOEMBOLISM; THROMBOPHILIA; UNITED STATES; VENOUS THROMBOSIS;

EID: 0344394967     PISSN: 00247758     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Weitz JI, Hirsh J: New anticoagulant drugs. Chest 2001;119:95S-107S
2. White RH: The epidemiology of venous thromboembolism. Circulation (suppl 1) 2003;107:4-8
3. Silverstein MD, Heit JA, Mohr DN, et al: Trends in the incidence of deep vein thrombosis and pulmonary embolism: A 25-year population-based study. Arch Intern Med 1998;158:585-593
4. Heit JA: Venous thromboembolism epidemiology: Implications for prevention and management. Semin Thromb Hemost (suppl) 2002;28:3-13
5. Heit JA, Silverstein MD, Mohr DN, et al: Predictors of survival after deep vein thrombosis and pulmonary embolism: A population-based, cohort study. Arch Intern Med 1999;159:445-453
6. Heit JA: Prevention of venous thromboembolism. Clin Geriatr Med 2001;17:71-92
7. Anderson FA Jr, Spencer FA: Risk factors for venous thromboembolism. Circulation (suppl 1) 2003;107:9-16
8. Sellman JS, Holman RL: Thromboembolism during pregnancy: Risks, challenges, and recommendations. Postgrad Med 2000;108:71-84
9. Cohen AT: Venous thromboembolic disease management of the nonsurgical moderate- and high-risk patient. Semin Hematol 2000;37:19-22
10. Clagett GP, Anderson FA Jr, Geerts W, et al: Prevention of venous thromboembolism. Chest 1998;114:531S-560S
11. Turpie AG: Optimizing prophylaxis of venous thromboembolism. Semin Thromb Hemost (suppl) 2002;28:25-32
12. Otten HM, Prins MH, Smorenburg SM, et al: Risk assessment and prophylaxis of venous thromboembolism in non-surgical patients: Cancer as a risk factor. Haemostasis (suppl) 2000;30:72-76
13. Bergqvist D: Venous thromboembolism and cancer: Prevention of VTE. Thromb Res 2001;102:V209-213
14. De Stefano V, Finazzi G, Mannucci PM: Inherited thrombophilia: Pathogenesis, clinical syndromes, and management. Blood 1996;87:3531-3544
15. Poort SR, Rosendaal FR, Reitsma PH, et al: A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703
16. Goldhaber SZ, Morrison RB: Pulmonary embolism and deep vein thrombosis. Circulation 2002;106:1436-1438
17. Lee RW: Pulmonary embolism. Chest Surg Clin North Am 2002;12:417-437
18. Turpie AG, Buller HR: Benefit of selective factor inhibition. Semin Thromb Hemost (suppl) 2002;28:49-50
19. Haines ST, Bussey HI: Diagnosis of deep vein thrombosis. Am J Health Syst Pharm 1997;54:66-74
20. Realini JP, Goldzieher JW: Oral contraceptives and cardiovascular disease: A critique of the epidemiologic studies. Am J Obstet Gynecol 1985;152:729-798
21. Douketis JD, Ginsberg JS, Holbrook A, et al: A reevaluation of the risk for venous thromboembolism with the use of oral contraceptives and hormone replacement therapy. Arch Intern Med 1997;157:1522-1530
22. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1582-1588
23. Jick H, Jick SS, Gurewich V, et al: Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995;346:1589-1593
24. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, et al: Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-1596
25. Spitzer WO, Lewis MA, Heinemann LA: Third generation oral contraceptives and risk of venous thromboembolic disorders: An international case-control study. BMJ 1996;312:83-88
26. Barger AP, Hurley R: Evaluation of the hypercoagulable state: Whom to screen, how to test and treat. Postgrad Med 2000;108:59-66
27. Enders JM, Burke JM, Dobesh PP: Prevention of venous thromboembolism in acute medical illness. Pharmacotherapy 2002;22:1564-1578
28. Davidson BL: DVT treatment in 2000: State of the art. Orthopedics 2000;23:S651-S654
29. Tapson VF, Carroll BA, Davidson BL, et al: The diagnostic approach to acute venous thromboembolism: Clinical practice guideline: American Thoracic Society. Am J Respir Crit Care Med 1999;160:1043-1066
30. Cook D, McMullin J, Hodder R, et al: Prevention and diagnosis of venous thromboembolism in critically ill patients: A Canadian survey. Crit Care 2001;5:336-342
31. Elliott CG: Modalities for assessing deep vein thrombosis and pulmonary embolism. In Managment and Prevention of Thrombosis in Primary Care. Edited by J Spandorfer, BA Konkle, GJ Merli. New York, Oxford University Press, 2001, pp 119-134
32. Aksamit TR: Thromboembolism occurrence and diagnosis in the medical intensive care unit. Semin Thromb Hemost 2001;27:47-57
33. Gill P, Nahum A: Improving detection of venous thromboembolism: New technology holds promise for early, precise diagnosis. Postgrad Med 2000;108:24-40
34. Hyers TM, Agnelli G, Hull RD, et al: Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119:176S-193S
35. Bauer KA: Selective inhibition of coagulation factors: Advances in antithrombotic therapy. Semin Thromb Hemost (suppl) 2002;28:15-24
36. Bussey H: Traditional anticoagulant therapy: Why abandon half a century of success? Am J Health Syst Pharm 2002;59: S3-S6
37. Hirsh J, Warkentin TE, Shaughnessy SG, et al: Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64S-94S
38. Hirsh J, Anand SS, Halperin JL, et al: Guide to anticoagulant therapy: Heparin: A statement for healthcare professionals from the American Heart Association. Circulation 2001;103:2994-3018
39. American College of Chest Physicians Quick Reference Guide for Clinicians. Sixth ACCP Consensus Conference on Antithrombotic Therapy (www.chestnet.org/downloads/guidelines/antithrombotic/qrg.pdf)
40. Buller HR: Treatment of symptomatic venous thromboembolism: Improving outcomes. Semin Thromb Hemost (suppl) 2002;28:41-48
41. Nutescu E, Racine E: Traditional versus modem anticoagulant strategies: Summary of the literature. Am J Health Syst Pharm 2002;59:S7-S14
42. Siragusa S, Cosmi B, Piovella F, et al: Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med 1996;100:269-277
43. Vichiendilokkul A: Breaking out of the silo: One health system's experience. Am J Health Syst Pharm 2002;59:S15-S17
44. Nurmohamed MT, MacGillavry MR: Long-term thromboprophylaxis in practice: How can it be implemented? Orthopedics 2000;23:S647-S650
45. Thomson L, O'Hara W: An overview of warfarin therapy. In Management and Prevention of Thrombosis in Primary Care. Edited by J Spandorfer, BA Konkle, GJ Merli. New York, Oxford University Press, 2001, pp 103-118
46. Ridker PM, Goldhaber SZ, Danielson E, et al: Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-1434
47. Agnelli G: Unresolved issues in the prevention and treatment of venous thromboembolism. Semin Thromb Hemost (suppl) 2002;28:33-40